# DKDComboMiner — top 100 unexplored cells

> Research-use only. Synthetic mock data. Not for clinical decision-making. IRB review required.

- Total cells scored: 235872
- Combo size up to: 2
- Weights: {'gap': 0.2, 'trend': 0.1, 'trial_gap': 0.1, 'kdigo': 0.15, 'mech': 0.2, 'feasibility': 0.2, 'faers_penalty': 0.15}

## Ranked hypothesis cards

## #1 (score 0.816)

### Hypothesis: Empagliflozin (EMPA), Liraglutide (LIRA) | KDIGO G2A1 | UACRV | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.816**
- Synthetic literature gap (pubmed_n / trend_5y%): 1 / +55%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=1 (gap=0.99), 5y trend +55% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #2 (score 0.803)

### Hypothesis: Dapagliflozin (DAPA), Dulaglutide (DULA) | KDIGO G3aA3 | UACR | T2DM_ASCVD

- Drug combo: Dapagliflozin (DAPA), Dulaglutide (DULA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.803**
- Synthetic literature gap (pubmed_n / trend_5y%): 9 / +51%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=9 (gap=0.95), 5y trend +51% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #3 (score 0.8029)

### Hypothesis: Finerenone (FINE), Semaglutide (SEMA) | KDIGO G1A1 | UACRV | T2DM_ASCVD

- Drug combo: Finerenone (FINE), Semaglutide (SEMA)
- Class signature: GLP1RA + MRA
- KDIGO stage: G1A1
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.8029**
- Synthetic literature gap (pubmed_n / trend_5y%): 0 / +49%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.8 | FAERS caution: 0.388 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=0 (gap=1.00), 5y trend +49% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.80; FAERS caution = 0.39 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #4 (score 0.8011)

### Hypothesis: Dulaglutide (DULA), Finerenone (FINE) | KDIGO G3aA2 | UACR | T2DM_ASCVD

- Drug combo: Dulaglutide (DULA), Finerenone (FINE)
- Class signature: GLP1RA + MRA
- KDIGO stage: G3aA2
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.8011**
- Synthetic literature gap (pubmed_n / trend_5y%): 8 / +54%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.8 | FAERS caution: 0.388 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=8 (gap=0.96), 5y trend +54% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.80; FAERS caution = 0.39 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #5 (score 0.801)

### Hypothesis: Dulaglutide (DULA), Empagliflozin (EMPA) | KDIGO G3aA1 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Dulaglutide (DULA), Empagliflozin (EMPA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.801**
- Synthetic literature gap (pubmed_n / trend_5y%): 6 / +57%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=6 (gap=0.97), 5y trend +57% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #6 (score 0.7995)

### Hypothesis: Canagliflozin (CANA), Perindopril (PERI) | KDIGO G2A1 | UACRV | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Perindopril (PERI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7995**
- Synthetic literature gap (pubmed_n / trend_5y%): 8 / +46%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=8 (gap=0.96), 5y trend +46% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #7 (score 0.7978)

### Hypothesis: Dapagliflozin (DAPA), Telmisartan (TELM) | KDIGO G3aA3 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Dapagliflozin (DAPA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7978**
- Synthetic literature gap (pubmed_n / trend_5y%): 1 / +49%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=1 (gap=0.99), 5y trend +49% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #8 (score 0.796)

### Hypothesis: Dulaglutide (DULA) | KDIGO G2A2 | UACR | T2DM_LEAN

- Drug combo: Dulaglutide (DULA)
- Class signature: GLP1RA
- KDIGO stage: G2A2
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.796**
- Synthetic literature gap (pubmed_n / trend_5y%): 30 / +58%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.85 | Mechanism: 0.7 | FAERS caution: 0.1 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=30 (gap=0.85), 5y trend +58% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.85 / Mechanism plausibility prior = 0.70; FAERS caution = 0.10 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #9 (score 0.7939)

### Hypothesis: Ramipril (RAMI) | KDIGO G3aA3 | UACRV | T2DM_LEAN

- Drug combo: Ramipril (RAMI)
- Class signature: RAS
- KDIGO stage: G3aA3
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7939**
- Synthetic literature gap (pubmed_n / trend_5y%): 14 / +50%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=14 (gap=0.93), 5y trend +50% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #10 (score 0.792)

### Hypothesis: Dulaglutide (DULA) | KDIGO G2A1 | UACRV | T2DM_ASCVD

- Drug combo: Dulaglutide (DULA)
- Class signature: GLP1RA
- KDIGO stage: G2A1
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.792**
- Synthetic literature gap (pubmed_n / trend_5y%): 19 / +46%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.85 | Mechanism: 0.7 | FAERS caution: 0.1 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=19 (gap=0.91), 5y trend +46% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.85 / Mechanism plausibility prior = 0.70; FAERS caution = 0.10 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #11 (score 0.792)

### Hypothesis: Dapagliflozin (DAPA), Ramipril (RAMI) | KDIGO G3aA3 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.792**
- Synthetic literature gap (pubmed_n / trend_5y%): 18 / +48%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=18 (gap=0.91), 5y trend +48% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #12 (score 0.792)

### Hypothesis: Dulaglutide (DULA), Empagliflozin (EMPA) | KDIGO G1A3 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Dulaglutide (DULA), Empagliflozin (EMPA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.792**
- Synthetic literature gap (pubmed_n / trend_5y%): 30 / +59%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=30 (gap=0.85), 5y trend +59% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #13 (score 0.7903)

### Hypothesis: Empagliflozin (EMPA), Perindopril (PERI) | KDIGO G3aA3 | UACRV | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Perindopril (PERI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7903**
- Synthetic literature gap (pubmed_n / trend_5y%): 21 / +49%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=21 (gap=0.90), 5y trend +49% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #14 (score 0.7903)

### Hypothesis: Canagliflozin (CANA), Dulaglutide (DULA) | KDIGO G1A3 | UACRV | T2DM_LEAN

- Drug combo: Canagliflozin (CANA), Dulaglutide (DULA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7903**
- Synthetic literature gap (pubmed_n / trend_5y%): 13 / +54%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=13 (gap=0.94), 5y trend +54% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #15 (score 0.7886)

### Hypothesis: Perindopril (PERI), Semaglutide (SEMA) | KDIGO G2A1 | UACR | T2DM_ASCVD

- Drug combo: Perindopril (PERI), Semaglutide (SEMA)
- Class signature: GLP1RA + RAS
- KDIGO stage: G2A1
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7886**
- Synthetic literature gap (pubmed_n / trend_5y%): 8 / +50%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=8 (gap=0.96), 5y trend +50% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #16 (score 0.7868)

### Hypothesis: Dapagliflozin (DAPA), Liraglutide (LIRA) | KDIGO G3aA2 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA2
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.7868**
- Synthetic literature gap (pubmed_n / trend_5y%): 9 / +58%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=9 (gap=0.95), 5y trend +58% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #17 (score 0.7848)

### Hypothesis: Dapagliflozin (DAPA), Perindopril (PERI) | KDIGO G2A3 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Dapagliflozin (DAPA), Perindopril (PERI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7848**
- Synthetic literature gap (pubmed_n / trend_5y%): 39 / +59%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=39 (gap=0.80), 5y trend +59% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #18 (score 0.784)

### Hypothesis: Empagliflozin (EMPA), Semaglutide (SEMA) | KDIGO G1A1 | UACRV | T2DM_LEAN

- Drug combo: Empagliflozin (EMPA), Semaglutide (SEMA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.784**
- Synthetic literature gap (pubmed_n / trend_5y%): 33 / +55%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=33 (gap=0.83), 5y trend +55% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #19 (score 0.784)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G2A2 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A2
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.784**
- Synthetic literature gap (pubmed_n / trend_5y%): 6 / +52%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=6 (gap=0.97), 5y trend +52% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #20 (score 0.7827)

### Hypothesis: Ipragliflozin (IPRA), Perindopril (PERI) | KDIGO G3aA3 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Ipragliflozin (IPRA), Perindopril (PERI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7827**
- Synthetic literature gap (pubmed_n / trend_5y%): 6 / +58%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.775 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=6 (gap=0.97), 5y trend +58% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.78 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #21 (score 0.7813)

### Hypothesis: Canagliflozin (CANA), Losartan (LOSA) | KDIGO G2A1 | UACRV | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7813**
- Synthetic literature gap (pubmed_n / trend_5y%): 20 / +41%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=20 (gap=0.90), 5y trend +41% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #22 (score 0.7805)

### Hypothesis: Empagliflozin (EMPA), Liraglutide (LIRA) | KDIGO G2A3 | UACRV | T2DM_LEAN

- Drug combo: Empagliflozin (EMPA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A3
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7805**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +29%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +29% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #23 (score 0.7804)

### Hypothesis: Finerenone (FINE), Semaglutide (SEMA) | KDIGO G1A1 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Finerenone (FINE), Semaglutide (SEMA)
- Class signature: GLP1RA + MRA
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7804**
- Synthetic literature gap (pubmed_n / trend_5y%): 20 / +47%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.8 | FAERS caution: 0.388 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=20 (gap=0.90), 5y trend +47% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.80; FAERS caution = 0.39 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #24 (score 0.7798)

### Hypothesis: Canagliflozin (CANA), Liraglutide (LIRA) | KDIGO G1A3 | UACRV | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7798**
- Synthetic literature gap (pubmed_n / trend_5y%): 36 / +54%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=36 (gap=0.82), 5y trend +54% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #25 (score 0.7794)

### Hypothesis: Ramipril (RAMI), Semaglutide (SEMA) | KDIGO G1A2 | UACRV | T2DM_ASCVD

- Drug combo: Ramipril (RAMI), Semaglutide (SEMA)
- Class signature: GLP1RA + RAS
- KDIGO stage: G1A2
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7794**
- Synthetic literature gap (pubmed_n / trend_5y%): 16 / +49%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=16 (gap=0.92), 5y trend +49% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #26 (score 0.7788)

### Hypothesis: Empagliflozin (EMPA), Exenatide (EXEN) | KDIGO G3aA3 | UACRV | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Exenatide (EXEN)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7788**
- Synthetic literature gap (pubmed_n / trend_5y%): 12 / +52%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.775 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=12 (gap=0.94), 5y trend +52% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.78 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #27 (score 0.7784)

### Hypothesis: Ramipril (RAMI) | KDIGO G2A1 | EGFRSLOPE | T2DM_NONALB

- Drug combo: Ramipril (RAMI)
- Class signature: RAS
- KDIGO stage: G2A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_NONALB
- Composite score: **0.7784**
- Synthetic literature gap (pubmed_n / trend_5y%): 3 / +57%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=3 (gap=0.98), 5y trend +57% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #28 (score 0.7784)

### Hypothesis: Dulaglutide (DULA), Ramipril (RAMI) | KDIGO G1A1 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Dulaglutide (DULA), Ramipril (RAMI)
- Class signature: GLP1RA + RAS
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.7784**
- Synthetic literature gap (pubmed_n / trend_5y%): 12 / +45%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=12 (gap=0.94), 5y trend +45% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #29 (score 0.7783)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G2A2 | UACR | T2DM_RETINO

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A2
- Primary biomarker: UACR
- Target population: T2DM_RETINO
- Composite score: **0.7783**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +54%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +54% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #30 (score 0.7778)

### Hypothesis: Canagliflozin (CANA) | KDIGO G3aA1 | UACR | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA)
- Class signature: SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7778**
- Synthetic literature gap (pubmed_n / trend_5y%): 2 / +57%
- Synthetic KR active trials: 3
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.7 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=2 (gap=0.99), 5y trend +57% / Active KR trials (synthetic) = 3; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.70; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #31 (score 0.7774)

### Hypothesis: Perindopril (PERI) | KDIGO G1A3 | UACR | T2DM_LEAN

- Drug combo: Perindopril (PERI)
- Class signature: RAS
- KDIGO stage: G1A3
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7774**
- Synthetic literature gap (pubmed_n / trend_5y%): 23 / +54%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=23 (gap=0.89), 5y trend +54% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #32 (score 0.7768)

### Hypothesis: Dapagliflozin (DAPA), Ramipril (RAMI) | KDIGO G1A2 | UACR | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A2
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7768**
- Synthetic literature gap (pubmed_n / trend_5y%): 7 / +37%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=7 (gap=0.96), 5y trend +37% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #33 (score 0.7768)

### Hypothesis: Empagliflozin (EMPA), Liraglutide (LIRA) | KDIGO G2A2 | UACRV | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A2
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7768**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +26%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +26% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #34 (score 0.7766)

### Hypothesis: Canagliflozin (CANA), Telmisartan (TELM) | KDIGO G2A3 | UACRV | T2DM_NONALB

- Drug combo: Canagliflozin (CANA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A3
- Primary biomarker: UACRV
- Target population: T2DM_NONALB
- Composite score: **0.7766**
- Synthetic literature gap (pubmed_n / trend_5y%): 2 / +51%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=2 (gap=0.99), 5y trend +51% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #35 (score 0.7761)

### Hypothesis: Empagliflozin (EMPA), Perindopril (PERI) | KDIGO G1A3 | EGFRSLOPE | T2DM_RETINO

- Drug combo: Empagliflozin (EMPA), Perindopril (PERI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_RETINO
- Composite score: **0.7761**
- Synthetic literature gap (pubmed_n / trend_5y%): 10 / +57%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=10 (gap=0.95), 5y trend +57% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #36 (score 0.7743)

### Hypothesis: Canagliflozin (CANA), Exenatide (EXEN) | KDIGO G2A2 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Exenatide (EXEN)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A2
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7743**
- Synthetic literature gap (pubmed_n / trend_5y%): 9 / +46%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.775 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=9 (gap=0.95), 5y trend +46% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.78 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #37 (score 0.7739)

### Hypothesis: Losartan (LOSA) | KDIGO G1A1 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Losartan (LOSA)
- Class signature: RAS
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.7739**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +56%
- Synthetic KR active trials: 3
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +56% / Active KR trials (synthetic) = 3; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #38 (score 0.7729)

### Hypothesis: Telmisartan (TELM) | KDIGO G2A3 | UACR | T2DM_ASCVD

- Drug combo: Telmisartan (TELM)
- Class signature: RAS
- KDIGO stage: G2A3
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7729**
- Synthetic literature gap (pubmed_n / trend_5y%): 30 / +56%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=30 (gap=0.85), 5y trend +56% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #39 (score 0.7724)

### Hypothesis: Perindopril (PERI) | KDIGO G2A2 | UACR | T2DM_ASCVD

- Drug combo: Perindopril (PERI)
- Class signature: RAS
- KDIGO stage: G2A2
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7724**
- Synthetic literature gap (pubmed_n / trend_5y%): 18 / +56%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=18 (gap=0.91), 5y trend +56% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #40 (score 0.7712)

### Hypothesis: Finerenone (FINE), Liraglutide (LIRA) | KDIGO G3bA1 | UACRV | T2DM_LEAN

- Drug combo: Finerenone (FINE), Liraglutide (LIRA)
- Class signature: GLP1RA + MRA
- KDIGO stage: G3bA1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7712**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +48%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.8 | FAERS caution: 0.388 | KR IIS feasibility: 0.748
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +48% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.80; FAERS caution = 0.39 / Best matching KR cohort: KDA-REG (feasibility 0.75)


## #41 (score 0.7711)

### Hypothesis: Canagliflozin (CANA), Ramipril (RAMI) | KDIGO G1A2 | UACR | T2DM_NONALB

- Drug combo: Canagliflozin (CANA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A2
- Primary biomarker: UACR
- Target population: T2DM_NONALB
- Composite score: **0.7711**
- Synthetic literature gap (pubmed_n / trend_5y%): 0 / +55%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=0 (gap=1.00), 5y trend +55% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #42 (score 0.7704)

### Hypothesis: Dulaglutide (DULA), Ramipril (RAMI) | KDIGO G3aA1 | UACRV | T2DM_ASCVD

- Drug combo: Dulaglutide (DULA), Ramipril (RAMI)
- Class signature: GLP1RA + RAS
- KDIGO stage: G3aA1
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7704**
- Synthetic literature gap (pubmed_n / trend_5y%): 15 / +51%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=15 (gap=0.93), 5y trend +51% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #43 (score 0.7703)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G1A1 | EGFRSLOPE | T2DM_RETINO

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_RETINO
- Composite score: **0.7703**
- Synthetic literature gap (pubmed_n / trend_5y%): 17 / +58%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=17 (gap=0.92), 5y trend +58% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #44 (score 0.77)

### Hypothesis: Dapagliflozin (DAPA) | KDIGO G1A1 | UACRV | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA)
- Class signature: SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.77**
- Synthetic literature gap (pubmed_n / trend_5y%): 16 / +42%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.7 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=16 (gap=0.92), 5y trend +42% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.70; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #45 (score 0.7693)

### Hypothesis: Empagliflozin (EMPA) | KDIGO G1A1 | EGFRSLOPE | T2DM_NONALB

- Drug combo: Empagliflozin (EMPA)
- Class signature: SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_NONALB
- Composite score: **0.7693**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +50%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.7 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +50% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.70; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #46 (score 0.7688)

### Hypothesis: Empagliflozin (EMPA), Telmisartan (TELM) | KDIGO G3aA3 | UACRV | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7688**
- Synthetic literature gap (pubmed_n / trend_5y%): 25 / +55%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=25 (gap=0.88), 5y trend +55% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #47 (score 0.768)

### Hypothesis: Dapagliflozin (DAPA), Dulaglutide (DULA) | KDIGO G2A3 | UACRV | T2DM_ASCVD

- Drug combo: Dapagliflozin (DAPA), Dulaglutide (DULA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A3
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.768**
- Synthetic literature gap (pubmed_n / trend_5y%): 19 / +51%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=19 (gap=0.91), 5y trend +51% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #48 (score 0.768)

### Hypothesis: Canagliflozin (CANA), Liraglutide (LIRA) | KDIGO G2A1 | UACR | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.768**
- Synthetic literature gap (pubmed_n / trend_5y%): 24 / +55%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=24 (gap=0.88), 5y trend +55% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #49 (score 0.7679)

### Hypothesis: Losartan (LOSA) | KDIGO G1A2 | UACR | T2DM_LEAN

- Drug combo: Losartan (LOSA)
- Class signature: RAS
- KDIGO stage: G1A2
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7679**
- Synthetic literature gap (pubmed_n / trend_5y%): 0 / +28%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=0 (gap=1.00), 5y trend +28% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #50 (score 0.7675)

### Hypothesis: Canagliflozin (CANA), Ramipril (RAMI) | KDIGO G1A3 | UACR | T2DM_LEAN

- Drug combo: Canagliflozin (CANA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7675**
- Synthetic literature gap (pubmed_n / trend_5y%): 30 / +38%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=30 (gap=0.85), 5y trend +38% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #51 (score 0.7672)

### Hypothesis: Liraglutide (LIRA), Perindopril (PERI) | KDIGO G3aA3 | UACR | T2DM_RETINO

- Drug combo: Liraglutide (LIRA), Perindopril (PERI)
- Class signature: GLP1RA + RAS
- KDIGO stage: G3aA3
- Primary biomarker: UACR
- Target population: T2DM_RETINO
- Composite score: **0.7672**
- Synthetic literature gap (pubmed_n / trend_5y%): 3 / +57%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=3 (gap=0.98), 5y trend +57% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #52 (score 0.7671)

### Hypothesis: Empagliflozin (EMPA) | KDIGO G1A2 | UACRV | T2DM_RETINO

- Drug combo: Empagliflozin (EMPA)
- Class signature: SGLT2i
- KDIGO stage: G1A2
- Primary biomarker: UACRV
- Target population: T2DM_RETINO
- Composite score: **0.7671**
- Synthetic literature gap (pubmed_n / trend_5y%): 5 / +59%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.7 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=5 (gap=0.97), 5y trend +59% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.70; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #53 (score 0.7666)

### Hypothesis: Finerenone (FINE), Liraglutide (LIRA) | KDIGO G3aA1 | UACR | T2DM_LEAN

- Drug combo: Finerenone (FINE), Liraglutide (LIRA)
- Class signature: GLP1RA + MRA
- KDIGO stage: G3aA1
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7666**
- Synthetic literature gap (pubmed_n / trend_5y%): 10 / +38%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.8 | FAERS caution: 0.388 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=10 (gap=0.95), 5y trend +38% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.80; FAERS caution = 0.39 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #54 (score 0.7665)

### Hypothesis: Losartan (LOSA), Semaglutide (SEMA) | KDIGO G3bA3 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Losartan (LOSA), Semaglutide (SEMA)
- Class signature: GLP1RA + RAS
- KDIGO stage: G3bA3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7665**
- Synthetic literature gap (pubmed_n / trend_5y%): 0 / +47%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.748
- Rationale: Synthetic PubMed n=0 (gap=1.00), 5y trend +47% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.75)


## #55 (score 0.7663)

### Hypothesis: Dapagliflozin (DAPA), Liraglutide (LIRA) | KDIGO G3aA1 | UACRV | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7663**
- Synthetic literature gap (pubmed_n / trend_5y%): 12 / +54%
- Synthetic KR active trials: 3
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=12 (gap=0.94), 5y trend +54% / Active KR trials (synthetic) = 3; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #56 (score 0.7658)

### Hypothesis: Dapagliflozin (DAPA), Perindopril (PERI) | KDIGO G2A1 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA), Perindopril (PERI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.7658**
- Synthetic literature gap (pubmed_n / trend_5y%): 13 / +23%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=13 (gap=0.94), 5y trend +23% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #57 (score 0.7658)

### Hypothesis: Empagliflozin (EMPA), Semaglutide (SEMA) | KDIGO G1A2 | EGFRSLOPE | T2DM_HFPEF

- Drug combo: Empagliflozin (EMPA), Semaglutide (SEMA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A2
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_HFPEF
- Composite score: **0.7658**
- Synthetic literature gap (pubmed_n / trend_5y%): 1 / +43%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=1 (gap=0.99), 5y trend +43% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #58 (score 0.7656)

### Hypothesis: Liraglutide (LIRA), Losartan (LOSA) | KDIGO G1A3 | UACR | T2DM_LEAN

- Drug combo: Liraglutide (LIRA), Losartan (LOSA)
- Class signature: GLP1RA + RAS
- KDIGO stage: G1A3
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7656**
- Synthetic literature gap (pubmed_n / trend_5y%): 41 / +58%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=41 (gap=0.80), 5y trend +58% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #59 (score 0.7653)

### Hypothesis: Canagliflozin (CANA), Losartan (LOSA) | KDIGO G3aA1 | UACR | T2DM_LEAN

- Drug combo: Canagliflozin (CANA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7653**
- Synthetic literature gap (pubmed_n / trend_5y%): 6 / +17%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=6 (gap=0.97), 5y trend +17% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #60 (score 0.7646)

### Hypothesis: Perindopril (PERI), Tirzepatide (TIRZ) | KDIGO G2A1 | UACR | T2DM_ASCVD

- Drug combo: Perindopril (PERI), Tirzepatide (TIRZ)
- Class signature: GLP1RA + RAS
- KDIGO stage: G2A1
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7646**
- Synthetic literature gap (pubmed_n / trend_5y%): 2 / +53%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.7 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=2 (gap=0.99), 5y trend +53% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.70 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #61 (score 0.7643)

### Hypothesis: Dapagliflozin (DAPA), Telmisartan (TELM) | KDIGO G1A2 | UACRV | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A2
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7643**
- Synthetic literature gap (pubmed_n / trend_5y%): 37 / +51%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=37 (gap=0.81), 5y trend +51% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #62 (score 0.7636)

### Hypothesis: Canagliflozin (CANA), Semaglutide (SEMA) | KDIGO G1A3 | EGFRSLOPE | T2DM_HFPEF

- Drug combo: Canagliflozin (CANA), Semaglutide (SEMA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_HFPEF
- Composite score: **0.7636**
- Synthetic literature gap (pubmed_n / trend_5y%): 12 / +50%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=12 (gap=0.94), 5y trend +50% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #63 (score 0.7635)

### Hypothesis: Dapagliflozin (DAPA) | KDIGO G3aA1 | UACR | T2DM_LEAN

- Drug combo: Dapagliflozin (DAPA)
- Class signature: SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7635**
- Synthetic literature gap (pubmed_n / trend_5y%): 5 / +38%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.7 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=5 (gap=0.97), 5y trend +38% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.70; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #64 (score 0.7635)

### Hypothesis: Empagliflozin (EMPA), Telmisartan (TELM) | KDIGO G2A2 | UACR | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A2
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7635**
- Synthetic literature gap (pubmed_n / trend_5y%): 24 / +40%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=24 (gap=0.88), 5y trend +40% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #65 (score 0.7634)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G3bA2 | UACR | T2DM_ASCVD

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3bA2
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7634**
- Synthetic literature gap (pubmed_n / trend_5y%): 14 / +43%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.748
- Rationale: Synthetic PubMed n=14 (gap=0.93), 5y trend +43% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.75)


## #66 (score 0.7634)

### Hypothesis: Eplerenone (EPLE), Liraglutide (LIRA) | KDIGO G3aA2 | UACR | T2DM_ASCVD

- Drug combo: Eplerenone (EPLE), Liraglutide (LIRA)
- Class signature: GLP1RA + MRA
- KDIGO stage: G3aA2
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7634**
- Synthetic literature gap (pubmed_n / trend_5y%): 2 / +55%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.625 | Mechanism: 0.8 | FAERS caution: 0.388 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=2 (gap=0.99), 5y trend +55% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.62 / Mechanism plausibility prior = 0.80; FAERS caution = 0.39 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #67 (score 0.7633)

### Hypothesis: Dapagliflozin (DAPA), Liraglutide (LIRA) | KDIGO G3aA1 | UACRV | T2DM_HFPEF

- Drug combo: Dapagliflozin (DAPA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: UACRV
- Target population: T2DM_HFPEF
- Composite score: **0.7633**
- Synthetic literature gap (pubmed_n / trend_5y%): 21 / +57%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=21 (gap=0.90), 5y trend +57% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #68 (score 0.7631)

### Hypothesis: Empagliflozin (EMPA), Telmisartan (TELM) | KDIGO G2A1 | UACRV | T2DM_HFPEF

- Drug combo: Empagliflozin (EMPA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: UACRV
- Target population: T2DM_HFPEF
- Composite score: **0.7631**
- Synthetic literature gap (pubmed_n / trend_5y%): 13 / +49%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=13 (gap=0.94), 5y trend +49% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #69 (score 0.7625)

### Hypothesis: Dapagliflozin (DAPA), Ramipril (RAMI) | KDIGO G1A2 | UACRV | T2DM_ASCVD

- Drug combo: Dapagliflozin (DAPA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A2
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7625**
- Synthetic literature gap (pubmed_n / trend_5y%): 20 / +36%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=20 (gap=0.90), 5y trend +36% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #70 (score 0.7623)

### Hypothesis: Dapagliflozin (DAPA), Semaglutide (SEMA) | KDIGO G2A1 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Dapagliflozin (DAPA), Semaglutide (SEMA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7623**
- Synthetic literature gap (pubmed_n / trend_5y%): 6 / +46%
- Synthetic KR active trials: 3
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=6 (gap=0.97), 5y trend +46% / Active KR trials (synthetic) = 3; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #71 (score 0.7623)

### Hypothesis: Dulaglutide (DULA), Empagliflozin (EMPA) | KDIGO G1A2 | EGFRSLOPE | T2DM_HFPEF

- Drug combo: Dulaglutide (DULA), Empagliflozin (EMPA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A2
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_HFPEF
- Composite score: **0.7623**
- Synthetic literature gap (pubmed_n / trend_5y%): 2 / +51%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=2 (gap=0.99), 5y trend +51% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #72 (score 0.7621)

### Hypothesis: Telmisartan (TELM) | KDIGO G2A3 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Telmisartan (TELM)
- Class signature: RAS
- KDIGO stage: G2A3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7621**
- Synthetic literature gap (pubmed_n / trend_5y%): 37 / +53%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=37 (gap=0.81), 5y trend +53% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #73 (score 0.7615)

### Hypothesis: Dulaglutide (DULA), Empagliflozin (EMPA) | KDIGO G3aA1 | UACRV | T2DM_LEAN

- Drug combo: Dulaglutide (DULA), Empagliflozin (EMPA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7615**
- Synthetic literature gap (pubmed_n / trend_5y%): 28 / +53%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=28 (gap=0.86), 5y trend +53% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #74 (score 0.7615)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G1A1 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.7615**
- Synthetic literature gap (pubmed_n / trend_5y%): 41 / +52%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=41 (gap=0.80), 5y trend +52% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #75 (score 0.7615)

### Hypothesis: Canagliflozin (CANA), Liraglutide (LIRA) | KDIGO G3aA2 | UACR | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA2
- Primary biomarker: UACR
- Target population: T2DM_ASCVD
- Composite score: **0.7615**
- Synthetic literature gap (pubmed_n / trend_5y%): 43 / +55%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=43 (gap=0.79), 5y trend +55% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #76 (score 0.7613)

### Hypothesis: Dapagliflozin (DAPA), Liraglutide (LIRA) | KDIGO G3aA3 | UACRV | T2DM_NONALB

- Drug combo: Dapagliflozin (DAPA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: UACRV
- Target population: T2DM_NONALB
- Composite score: **0.7613**
- Synthetic literature gap (pubmed_n / trend_5y%): 23 / +57%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=23 (gap=0.89), 5y trend +57% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #77 (score 0.7613)

### Hypothesis: Canagliflozin (CANA), Exenatide (EXEN) | KDIGO G2A1 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Canagliflozin (CANA), Exenatide (EXEN)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.7613**
- Synthetic literature gap (pubmed_n / trend_5y%): 27 / +50%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.775 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=27 (gap=0.86), 5y trend +50% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.78 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #78 (score 0.7611)

### Hypothesis: Canagliflozin (CANA), Ramipril (RAMI) | KDIGO G1A3 | EGFRSLOPE | T2DM_RETINO

- Drug combo: Canagliflozin (CANA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_RETINO
- Composite score: **0.7611**
- Synthetic literature gap (pubmed_n / trend_5y%): 5 / +41%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=5 (gap=0.97), 5y trend +41% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #79 (score 0.761)

### Hypothesis: Exenatide (EXEN) | KDIGO G3aA2 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Exenatide (EXEN)
- Class signature: GLP1RA
- KDIGO stage: G3aA2
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.761**
- Synthetic literature gap (pubmed_n / trend_5y%): 10 / +50%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.55 | Mechanism: 0.7 | FAERS caution: 0.1 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=10 (gap=0.95), 5y trend +50% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.55 / Mechanism plausibility prior = 0.70; FAERS caution = 0.10 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #80 (score 0.761)

### Hypothesis: Canagliflozin (CANA), Ramipril (RAMI) | KDIGO G2A1 | UACRV | T2DM_LEAN

- Drug combo: Canagliflozin (CANA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.761**
- Synthetic literature gap (pubmed_n / trend_5y%): 19 / +44%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=19 (gap=0.91), 5y trend +44% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #81 (score 0.7607)

### Hypothesis: Canagliflozin (CANA), Liraglutide (LIRA) | KDIGO G3bA1 | EGFRSLOPE | T2DM_RETINO

- Drug combo: Canagliflozin (CANA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3bA1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_RETINO
- Composite score: **0.7607**
- Synthetic literature gap (pubmed_n / trend_5y%): 0 / +55%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.598
- Rationale: Synthetic PubMed n=0 (gap=1.00), 5y trend +55% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.60)


## #82 (score 0.7605)

### Hypothesis: Empagliflozin (EMPA), Semaglutide (SEMA) | KDIGO G1A1 | UACR | T2DM_LEAN

- Drug combo: Empagliflozin (EMPA), Semaglutide (SEMA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7605**
- Synthetic literature gap (pubmed_n / trend_5y%): 24 / +29%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=24 (gap=0.88), 5y trend +29% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #83 (score 0.7602)

### Hypothesis: Ramipril (RAMI) | KDIGO G3bA3 | UACR | T2DM_LEAN

- Drug combo: Ramipril (RAMI)
- Class signature: RAS
- KDIGO stage: G3bA3
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7602**
- Synthetic literature gap (pubmed_n / trend_5y%): 5 / +47%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.748
- Rationale: Synthetic PubMed n=5 (gap=0.97), 5y trend +47% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.75)


## #84 (score 0.7601)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G1A3 | UACRV | T2DM_NONALB

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: UACRV
- Target population: T2DM_NONALB
- Composite score: **0.7601**
- Synthetic literature gap (pubmed_n / trend_5y%): 1 / +37%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=1 (gap=0.99), 5y trend +37% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #85 (score 0.76)

### Hypothesis: Empagliflozin (EMPA), Exenatide (EXEN) | KDIGO G3aA2 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Empagliflozin (EMPA), Exenatide (EXEN)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA2
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.76**
- Synthetic literature gap (pubmed_n / trend_5y%): 12 / +57%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 0.775 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=12 (gap=0.94), 5y trend +57% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 0.78 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #86 (score 0.7598)

### Hypothesis: Dapagliflozin (DAPA), Semaglutide (SEMA) | KDIGO G3aA3 | EGFRSLOPE | T2DM_RETINO

- Drug combo: Dapagliflozin (DAPA), Semaglutide (SEMA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G3aA3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_RETINO
- Composite score: **0.7598**
- Synthetic literature gap (pubmed_n / trend_5y%): 27 / +59%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=27 (gap=0.86), 5y trend +59% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #87 (score 0.7598)

### Hypothesis: Dapagliflozin (DAPA), Telmisartan (TELM) | KDIGO G3aA1 | UACRV | T2DM_HFPEF

- Drug combo: Dapagliflozin (DAPA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA1
- Primary biomarker: UACRV
- Target population: T2DM_HFPEF
- Composite score: **0.7598**
- Synthetic literature gap (pubmed_n / trend_5y%): 0 / +56%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=0 (gap=1.00), 5y trend +56% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #88 (score 0.7593)

### Hypothesis: Empagliflozin (EMPA), Perindopril (PERI) | KDIGO G2A1 | UACR | T2DM_LEAN

- Drug combo: Empagliflozin (EMPA), Perindopril (PERI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A1
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7593**
- Synthetic literature gap (pubmed_n / trend_5y%): 32 / +33%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=32 (gap=0.84), 5y trend +33% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #89 (score 0.7591)

### Hypothesis: Canagliflozin (CANA), Telmisartan (TELM) | KDIGO G3bA3 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Telmisartan (TELM)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3bA3
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7591**
- Synthetic literature gap (pubmed_n / trend_5y%): 22 / +56%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.748
- Rationale: Synthetic PubMed n=22 (gap=0.89), 5y trend +56% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.75)


## #90 (score 0.759)

### Hypothesis: Canagliflozin (CANA) | KDIGO G1A1 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA)
- Class signature: SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.759**
- Synthetic literature gap (pubmed_n / trend_5y%): 47 / +48%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.7 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=47 (gap=0.77), 5y trend +48% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.70; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #91 (score 0.7589)

### Hypothesis: Dulaglutide (DULA), Perindopril (PERI) | KDIGO G1A1 | UACRV | T2DM_LEAN

- Drug combo: Dulaglutide (DULA), Perindopril (PERI)
- Class signature: GLP1RA + RAS
- KDIGO stage: G1A1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7589**
- Synthetic literature gap (pubmed_n / trend_5y%): 29 / +43%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=29 (gap=0.85), 5y trend +43% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #92 (score 0.7589)

### Hypothesis: Dulaglutide (DULA), Perindopril (PERI) | KDIGO G1A2 | UACRV | T2DM_LEAN

- Drug combo: Dulaglutide (DULA), Perindopril (PERI)
- Class signature: GLP1RA + RAS
- KDIGO stage: G1A2
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.7589**
- Synthetic literature gap (pubmed_n / trend_5y%): 9 / +37%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.65 | FAERS caution: 0.237 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=9 (gap=0.95), 5y trend +37% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.65; FAERS caution = 0.24 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #93 (score 0.7588)

### Hypothesis: Canagliflozin (CANA), Semaglutide (SEMA) | KDIGO G1A3 | UACRV | T2DM_ASCVD

- Drug combo: Canagliflozin (CANA), Semaglutide (SEMA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A3
- Primary biomarker: UACRV
- Target population: T2DM_ASCVD
- Composite score: **0.7588**
- Synthetic literature gap (pubmed_n / trend_5y%): 27 / +40%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=27 (gap=0.86), 5y trend +40% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #94 (score 0.7587)

### Hypothesis: Empagliflozin (EMPA), Finerenone (FINE) | KDIGO G1A1 | EGFRSLOPE | T2DM_RETINO

- Drug combo: Empagliflozin (EMPA), Finerenone (FINE)
- Class signature: MRA + SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_RETINO
- Composite score: **0.7587**
- Synthetic literature gap (pubmed_n / trend_5y%): 13 / +48%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.92 | FAERS caution: 0.588 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=13 (gap=0.94), 5y trend +48% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.92; FAERS caution = 0.59 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #95 (score 0.7587)

### Hypothesis: Finerenone (FINE), Liraglutide (LIRA) | KDIGO G3bA1 | EGFRSLOPE | T2DM_LEAN

- Drug combo: Finerenone (FINE), Liraglutide (LIRA)
- Class signature: GLP1RA + MRA
- KDIGO stage: G3bA1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_LEAN
- Composite score: **0.7587**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +38%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.8 | FAERS caution: 0.388 | KR IIS feasibility: 0.748
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +38% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.80; FAERS caution = 0.39 / Best matching KR cohort: KDA-REG (feasibility 0.75)


## #96 (score 0.7586)

### Hypothesis: Canagliflozin (CANA), Ramipril (RAMI) | KDIGO G3aA2 | UACRV | T2DM_RETINO

- Drug combo: Canagliflozin (CANA), Ramipril (RAMI)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3aA2
- Primary biomarker: UACRV
- Target population: T2DM_RETINO
- Composite score: **0.7586**
- Synthetic literature gap (pubmed_n / trend_5y%): 10 / +53%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.704
- Rationale: Synthetic PubMed n=10 (gap=0.95), 5y trend +53% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.70)


## #97 (score 0.7584)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G3bA1 | UACR | T2DM_NONALB

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G3bA1
- Primary biomarker: UACR
- Target population: T2DM_NONALB
- Composite score: **0.7584**
- Synthetic literature gap (pubmed_n / trend_5y%): 4 / +55%
- Synthetic KR active trials: 0
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.598
- Rationale: Synthetic PubMed n=4 (gap=0.98), 5y trend +55% / Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.60)


## #98 (score 0.7583)

### Hypothesis: Liraglutide (LIRA) | KDIGO G2A1 | EGFRSLOPE | T2DM_ASCVD

- Drug combo: Liraglutide (LIRA)
- Class signature: GLP1RA
- KDIGO stage: G2A1
- Primary biomarker: EGFRSLOPE
- Target population: T2DM_ASCVD
- Composite score: **0.7583**
- Synthetic literature gap (pubmed_n / trend_5y%): 49 / +53%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.85 | Mechanism: 0.7 | FAERS caution: 0.1 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=49 (gap=0.76), 5y trend +53% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.85 / Mechanism plausibility prior = 0.70; FAERS caution = 0.10 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #99 (score 0.7582)

### Hypothesis: Empagliflozin (EMPA), Losartan (LOSA) | KDIGO G2A2 | UACR | T2DM_LEAN

- Drug combo: Empagliflozin (EMPA), Losartan (LOSA)
- Class signature: RAS + SGLT2i
- KDIGO stage: G2A2
- Primary biomarker: UACR
- Target population: T2DM_LEAN
- Composite score: **0.7582**
- Synthetic literature gap (pubmed_n / trend_5y%): 8 / +33%
- Synthetic KR active trials: 2
- KDIGO 2024 strength avg: 1.0 | Mechanism: 0.72 | FAERS caution: 0.3 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=8 (gap=0.96), 5y trend +33% / Active KR trials (synthetic) = 2; KDIGO 2024 strength avg = 1.00 / Mechanism plausibility prior = 0.72; FAERS caution = 0.30 / Best matching KR cohort: KDA-REG (feasibility 0.88)


## #100 (score 0.758)

### Hypothesis: Canagliflozin (CANA), Liraglutide (LIRA) | KDIGO G1A1 | UACRV | T2DM_LEAN

- Drug combo: Canagliflozin (CANA), Liraglutide (LIRA)
- Class signature: GLP1RA + SGLT2i
- KDIGO stage: G1A1
- Primary biomarker: UACRV
- Target population: T2DM_LEAN
- Composite score: **0.758**
- Synthetic literature gap (pubmed_n / trend_5y%): 34 / +45%
- Synthetic KR active trials: 1
- KDIGO 2024 strength avg: 0.925 | Mechanism: 0.88 | FAERS caution: 0.45 | KR IIS feasibility: 0.88
- Rationale: Synthetic PubMed n=34 (gap=0.83), 5y trend +45% / Active KR trials (synthetic) = 1; KDIGO 2024 strength avg = 0.93 / Mechanism plausibility prior = 0.88; FAERS caution = 0.45 / Best matching KR cohort: KDA-REG (feasibility 0.88)


---

## Grant-ready specific aims (top-1)

# Grant-Ready Specific Aims: Empagliflozin + Liraglutide in DKD G2A1

> Research-use only. IRB approval and expert review required prior to any clinical application. Synthetic data only.

## Specific Aims
**Aim 1.** Determine the effect of Empagliflozin + Liraglutide on UACRV trajectory in T2DM_ASCVD with KDIGO G2A1 DKD over 52 weeks (synthetic preliminary data: gap-score 0.816; current Korea active trials = 0).

**Aim 2.** Identify mechanistic mediators (mechanism plausibility prior 0.88) using paired plasma + urine multi-omics in a Korean IIS cohort with feasibility 0.88.

**Aim 3.** Build a Korean-cohort-validated risk-stratification tool combining UACRV with KDIGO 2024 (combo strength 0.925) for treatment selection.

## Innovation
- Class signature GLP1RA + SGLT2i addresses an unexplored cell of the DKD therapeutic ontology.
- Korean lean / non-albuminuric DKD phenotype is underrepresented in pivotal trials (FLOW, EMPA-KIDNEY, FIDELIO/FIGARO).

## Approach
- Design: prospective IIS, parallel-arm, target N derived from KR cohort coverage.
- Outcomes: primary UACRV change at 52w; secondary eGFR slope, hard renal endpoints.
- Safety monitoring informed by synthetic FAERS caution score = 0.45.

## Preliminary Data (synthetic)
- Synthetic PubMed n=1 (gap=0.99), 5y trend +55%
- Active KR trials (synthetic) = 0; KDIGO 2024 strength avg = 0.93
- Mechanism plausibility prior = 0.88; FAERS caution = 0.45
- Best matching KR cohort: KDA-REG (feasibility 0.88)

## Deliverables
- KDA / KSAD abstracts, peer-reviewed manuscript, KR cohort-derived RWE evidence package.


## KDA / KSAD abstract draft (top-1)

# KDA / KSAD Abstract Draft (synthetic preliminary)

> Research-use only. Synthetic mock data; not an actual study result.

## English (target ~250 words)
**Title.** Empagliflozin + Liraglutide for KDIGO G2A1 diabetic kidney disease in T2DM_ASCVD: a Korean investigator-initiated study proposal.

**Background.** Despite SGLT2i, GLP-1RA, and finerenone-class advances, the (drug-combo x stage x biomarker x population) cell defined by Empagliflozin + Liraglutide / G2A1 / UACRV / T2DM_ASCVD remains underexplored (synthetic literature n=1, KR active trials=0).

**Methods.** Using a DKD therapeutic ontology of 23 drugs, 18 KDIGO stages, 7 biomarkers, and 8 populations, we systematically screened ~70,000 cells. We integrated synthetic literature counts, KR cohort feasibility, KDIGO 2024 recommendation strength, mechanism plausibility, and FAERS-style safety priors into a composite score.

**Results.** This cell scored 0.816 (top-tier). KDIGO 2024 strength 0.925, mechanism plausibility 0.88, KR IIS feasibility 0.88, FAERS caution 0.45.

**Conclusion.** A KR IIS evaluating Empagliflozin + Liraglutide on UACRV in T2DM_ASCVD with G2A1 DKD is high-priority; preliminary feasibility supports KDA / KSAD pursuit.

## 한국어 (약 250 단어)
**제목.** T2DM_ASCVD 환자에서 KDIGO G2A1 당뇨병성 신증에 대한 Empagliflozin + Liraglutide 병용 효과: 한국형 연구자 주도 임상시험 제안.

**배경.** SGLT2 억제제·GLP-1 수용체 작용제·non-steroidal MRA의 발전에도 불구하고, Empagliflozin + Liraglutide / G2A1 / UACRV / T2DM_ASCVD 조합은 미탐색 영역으로 남아있다 (합성 문헌 n=1, 한국 활성 시험 0).

**방법.** 23개 약물·18개 KDIGO 단계·7개 바이오마커·8개 인구학을 포함하는 DKD 치료 온톨로지를 구성하고 약 70,000개 cell을 체계적으로 스크리닝하였다. 합성 문헌 수, 한국 코호트 가용성, KDIGO 2024 권고 강도, 기전 타당성, FAERS 유사 안전성 prior를 가중합하여 복합 점수를 산출하였다.

**결과.** 본 cell의 점수 0.816 (상위권). KDIGO 강도 0.925, 기전 타당성 0.88, 한국 IIS 가능성 0.88, FAERS 주의 0.45.

**결론.** T2DM_ASCVD의 G2A1 단계에서 Empagliflozin + Liraglutide 병용이 UACRV에 미치는 영향을 평가하는 한국형 IIS는 우선순위가 높으며, 예비 가용성 평가가 KDA·KSAD 추진을 뒷받침한다.